TSE:PMN

ProMIS Neurosciences Competitors

C$0.22
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
C$0.22
Now: C$0.22
C$0.23
50-Day Range
C$0.12
MA: C$0.15
C$0.23
52-Week Range
C$0.08
Now: C$0.22
C$0.31
Volume249,291 shs
Average Volume439,089 shs
Market CapitalizationC$67.31 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

ProMIS Neurosciences (TSE:PMN) Vs. MDNA, ONC, EMC, IMV, ATE, and FRX

Should you be buying PMN stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to ProMIS Neurosciences, including Medicenna Therapeutics (MDNA), Oncolytics Biotech (ONC), Emblem (EMC), IMV (IMV), Antibe Therapeutics (ATE), and Fennec Pharmaceuticals (FRX).

Medicenna Therapeutics (TSE:MDNA) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Medicenna Therapeutics and ProMIS Neurosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicenna Therapeutics0000N/A
ProMIS Neurosciences0000N/A

Valuation and Earnings

This table compares Medicenna Therapeutics and ProMIS Neurosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/AN/AC($0.31)-16.44
ProMIS NeurosciencesC$1,787.0037,665.92C$-6,119,000.00C($0.02)-11.00

Medicenna Therapeutics has higher earnings, but lower revenue than ProMIS Neurosciences. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than ProMIS Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medicenna Therapeutics and ProMIS Neurosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicenna TherapeuticsN/AN/AN/A
ProMIS NeurosciencesN/AN/AN/A

Summary

ProMIS Neurosciences beats Medicenna Therapeutics on 3 of the 3 factors compared between the two stocks.

Oncolytics Biotech (TSE:ONC) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Profitability

This table compares Oncolytics Biotech and ProMIS Neurosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oncolytics BiotechN/AN/AN/A
ProMIS NeurosciencesN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Oncolytics Biotech and ProMIS Neurosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncolytics Biotech01202.67
ProMIS Neurosciences0000N/A

Oncolytics Biotech currently has a consensus price target of C$6.00, indicating a potential upside of 20.24%. Given Oncolytics Biotech's higher probable upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than ProMIS Neurosciences.

Earnings & Valuation

This table compares Oncolytics Biotech and ProMIS Neurosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncolytics BiotechN/AN/AN/AC($0.56)-8.91
ProMIS NeurosciencesC$1,787.0037,665.92C$-6,119,000.00C($0.02)-11.00

Oncolytics Biotech has higher earnings, but lower revenue than ProMIS Neurosciences. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Oncolytics Biotech beats ProMIS Neurosciences on 3 of the 5 factors compared between the two stocks.

Emblem (CVE:EMC) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares Emblem and ProMIS Neurosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emblem$5.71 million43.02C$-24,806,020.00($0.19)-9.89
ProMIS NeurosciencesC$1,787.0037,665.92C$-6,119,000.00C($0.02)-11.00

ProMIS Neurosciences has lower revenue, but higher earnings than Emblem. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Emblem and ProMIS Neurosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emblem0000N/A
ProMIS Neurosciences0000N/A

Profitability

This table compares Emblem and ProMIS Neurosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmblemN/AN/AN/A
ProMIS NeurosciencesN/AN/AN/A

Summary

ProMIS Neurosciences beats Emblem on 3 of the 5 factors compared between the two stocks.

IMV (TSE:IMV) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares IMV and ProMIS Neurosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMVC$3,000.0081,704.61C$-39,136,958.00C($0.58)-6.26
ProMIS NeurosciencesC$1,787.0037,665.92C$-6,119,000.00C($0.02)-11.00

ProMIS Neurosciences has lower revenue, but higher earnings than IMV. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IMV and ProMIS Neurosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMVN/AN/AN/A
ProMIS NeurosciencesN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for IMV and ProMIS Neurosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMV04002.00
ProMIS Neurosciences0000N/A

IMV currently has a consensus price target of C$5.08, suggesting a potential upside of 40.42%. Given IMV's higher probable upside, equities research analysts clearly believe IMV is more favorable than ProMIS Neurosciences.

Summary

IMV beats ProMIS Neurosciences on 4 of the 6 factors compared between the two stocks.

Antibe Therapeutics (TSE:ATE) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of recent ratings for Antibe Therapeutics and ProMIS Neurosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics00203.00
ProMIS Neurosciences0000N/A

Antibe Therapeutics currently has a consensus price target of C$7.75, suggesting a potential upside of 58.81%. Given Antibe Therapeutics' higher possible upside, research analysts plainly believe Antibe Therapeutics is more favorable than ProMIS Neurosciences.

Profitability

This table compares Antibe Therapeutics and ProMIS Neurosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe TherapeuticsN/AN/AN/A
ProMIS NeurosciencesN/AN/AN/A

Earnings and Valuation

This table compares Antibe Therapeutics and ProMIS Neurosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe TherapeuticsC$9.33 million23.80C$-35,814,009.00C($0.79)-6.20
ProMIS NeurosciencesC$1,787.0037,665.92C$-6,119,000.00C($0.02)-11.00

ProMIS Neurosciences has lower revenue, but higher earnings than Antibe Therapeutics. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Antibe Therapeutics beats ProMIS Neurosciences on 4 of the 7 factors compared between the two stocks.

Fennec Pharmaceuticals (TSE:FRX) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Fennec Pharmaceuticals and ProMIS Neurosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fennec Pharmaceuticals00203.00
ProMIS Neurosciences0000N/A

Profitability

This table compares Fennec Pharmaceuticals and ProMIS Neurosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fennec PharmaceuticalsN/AN/AN/A
ProMIS NeurosciencesN/AN/AN/A

Earnings & Valuation

This table compares Fennec Pharmaceuticals and ProMIS Neurosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$170,000.001,196.14C$-19,866,292.00C($0.76)-10.24
ProMIS NeurosciencesC$1,787.0037,665.92C$-6,119,000.00C($0.02)-11.00

ProMIS Neurosciences has lower revenue, but higher earnings than Fennec Pharmaceuticals. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


ProMIS Neurosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MDNA
Medicenna Therapeutics
0.5$5.08flatC$268.74 millionN/A-16.44
ONC
Oncolytics Biotech
1.0$4.99flatC$259.90 millionN/A-8.91News Coverage
Gap Down
EMC
Emblem
0.5$1.88flat$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.62flatC$245.11 millionC$3,000.00-6.26
ATE
Antibe Therapeutics
1.3$4.88flatC$222.07 millionC$9.33 million-6.20Gap Down
FRX
Fennec Pharmaceuticals
0.5$7.82flatC$203.34 millionC$170,000.00-10.24
RVX
Resverlogix
0.7$0.86flatC$202.07 millionN/A78.18Upcoming Earnings
HBP
Helix BioPharma
0.5$0.92flatC$129.84 millionN/A-16.73
IPA
ImmunoPrecise Antibodies
0.4$15.41flatC$123.03 millionC$17.18 million-72.01News Coverage
Gap Up
ACST
Acasti Pharma Inc. (ACST.V)
0.7$0.68flatC$88.79 millionC$81,000.0025.19Gap Down
NVH
Novoheart
0.5$0.53flatC$79.23 millionC$423,500.00-13.95
PDP
Pediapharm
0.5$0.30flatC$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.55flatC$60.20 millionC$11.64 million-10.78News Coverage
Gap Up
SBM
Sirona Biochem
0.5$0.38flatC$58.80 millionC$123,870.00-29.23
COV
Covalon Technologies
0.6$1.41flatC$37.44 millionC$23.84 million-5.92News Coverage
Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.29flatC$34.02 millionC$13.02 million-0.42
IGX
IntelGenx Technologies
0.9$0.57flatC$30.87 millionC$1.54 million-8.77News Coverage
QPT
Quest PharmaTech
0.8$0.11flatC$21.76 millionC$38,871.000.17High Trading Volume
CZO
Ceapro
0.7$0.72flatC$21.65 millionC$16.14 million21.82News Coverage
CTX
Crescita Therapeutics
0.6$0.86flatC$17.76 millionC$15.64 million430.00
KNE
Kane Biotech
0.4$0.17flatC$14.12 millionC$1.34 million-4.86
GSD
Devonian Health Group
0.5$0.27flatC$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09flatC$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06flatC$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60flatC$10.80 millionC$12.71 million-1.03Gap Down
BTI
Bioasis Technologies
0.7$0.39flatC$10.16 millionC$4.12 million35.45
HEM
Hemostemix
0.6$0.49flatC$9.07 millionN/A-2.92News Coverage
Gap Down
ICO
iCo Therapeutics
0.5$0.11flatC$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.36flatC$6.94 millionC$5.60 million6.57Gap Down
IOT
Innovotech
0.8$0.15flatC$6.52 millionC$1.04 million75.00Gap Up
BCT
BriaCell Therapeutics
0.5$6.40flatC$4.48 millionN/A-2.07High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08flatC$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04flatC$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03flatC$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01flatC$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.00
LTY
Liberty Biopharma
0.6$2.00flatC$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
SCYB
Scythian Biosciences
0.5$3.49flatC$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32flatC$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.